New Thomson Reuters Index reports health care inflation for privately insured; costs climbed 6.3% in year ending 2nd-qtr 2010

12 November 2010

The cost of health care for people in the USA with employer-sponsored health insurance climbed an estimated 6.3% for the year ending June 30, according to a new Thomson Reuters index.

The Thomson Reuters Healthcare Spending Index for Private Insurance measures historical and current levels of per capita health care spending for individuals whose coverage is provided by self-insured employers - a segment that represents about 25% of US health care expenditures.

"The index is accurate and detailed because it's based on the healthcare utilization of millions of Americans," said Gary Pickens, chief research officer at the Thomson Reuters Center for Healthcare Analytics. "That allows us to report on cost trends overall and for key components - hospitals, physicians, drugs, and patients' out-of-pocket costs," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical